<DOC>
	<DOCNO>NCT00562133</DOCNO>
	<brief_summary>The primary objective study evaluate postprandial time course nitrotyrosine injection insulin glulisine compare regular human insulin . The secondary objective evaluate postprandial time course follow efficacy parameter injection insulin glulisine compare regular insulin - Blood Glucose - Insulin - Intact proinsulin - Asymmetric dimethylarginine ( ADMA ) - Metal matrix proteasis ( MMP-9 ) - Oxidative status ( per ox ) - Interleukin 18 ( IL-18 ) - Free fatty acid ( FFA ) - Oxidised LDL ( ox-LDL ) - Microvascular blood circulation measure laser Doppler 37 °C ( LDF37 ) - Microvascular blood circulation measure laser Doppler 44 °C ( LDF44 )</brief_summary>
	<brief_title>Effect Insulin Glulisine v Regular Human Insulin Postprandial Endothelial Function Type 2 Diabetes</brief_title>
	<detailed_description>Phase III b Indication Type 2 Diabetes Trial Objectives 1 ) Primary objective : The primary objective study evaluate postprandial time course nitrotyrosine injection insulin glulisine compare regular human insulin . 2 ) Secondary objective : The secondary objective evaluate postprandial time course blood glucose , insulin , intact proinsulin , asymmetric dimethylarginine ( ADMA ) , metal matrix proteasis ( MMP-9 ) , free fatty acid ( FFA ) , oxidise LDL ( ox-LDL ) , oxidative status ( per ox ) , IL-18 well postprandial time course microvascular blood circulation measure laserdopplerflux 37 °C ( LDF37 ) 44 C ( LDF44 ) . Efficacy Variables Primary efficacy variablePostprandial time course nitrotyrosineSecondary efficacy variablePostprandial time course glucose , insulin , intact proinsulin , ADMA , MMP-9 , FFA , ox-LDL , per-ox , IL-18 well postprandial time course laserdopplerflux 37 °C 44 °C Safety Variables Incidence frequency adverse event evaluation safety laboratory parameter Medication/Dosage Insulin glulisine , dose 0.10 U/kg Regular Human Insulin , dose 0.10 U/kg Study Duration Duration study participation one patient : 5 - 43 day Overall duration study : 6 month Design Single-centre , open label , randomize , 2-way-crossover trial Population Male female type 2 diabetic patient 40 70 year HbA1c 6.5 % 9.9 % treated sulfonyurea alone combination Metformin stable dosage within last 3 month Sample Size N = 15</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>1 . Type 2 Diabetes mellitus accord ADA criterion 2 . HbA1c 6.5 % 9.9 % 3 . Monotherapy sulfonylurea combine Metformin stable dosage within last 3 month 4 . Age 40 70 year 5 . BMI &lt; 40 1 . Type 1 Diabetes mellitus 2 . PreTreatment insulin within last 6 month prior screen 3 . Treatment glitazones within last 6 month prior screen 4 . PreTreatment PPARyagonists , glinides glucosidase inhibitor within last 4 week prior screen 5 . Untreated hypertension stage IIIII accord WHO criteria 6 . Planned anticipated change antidiabetic and/or concomitant medication study participation 7 . Total Cholesterol &gt; 300 mg/dl ( anamnestically ) 8 . Hypokalemia ( K &lt; 3.5 mmol /l ) 9 . Major micro macrovascular complication judge investigator 10 . Tobacco use within last 12 month prior screen 11 . Drugs major impact endothelial function like nitrate etc . 12 . History drug alcohol abuse within last five year prior screen 13 . Anamnestic history hypersensitivity study drug drug similar chemical structure 14 . History severe multiple allergy 15 . Treatment investigational drug within 3 month prior screen 16 . Progressive fatal disease 17 . History significant cardiovascular , respiratory , gastrointestinal , hepatic ( ALAT and/or ASAT &gt; 3 time normal reference range ) , renal ( creatinine &gt; 1.1 mg/dL woman , &gt; 1.5 mg/dL men ) , neurological , psychiatric and/or haematological disease judge investigator 18 . Pregnancy breast feed 19 . Sexually active woman childbearing potential consistently correctly practice birth control implant , injectables , combine oral contraceptive , hormonal intrauterine device ( IUDs ) , sexual abstinence vasectomise partner 20 . Lack compliance similar reason , accord investigator , preclude satisfactory participation study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>